

3 December 2021

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Alcidion signs contract with Leidos Australia

- Alcidion, as part of a Consortium led by Leidos Australia, has been awarded a contract to deliver key capability for a Healthcare IT project for the Commonwealth of Australia
- Alcidion will provide the Longitudinal Health Record via its Miya Precision platform
- Initial value of contract to Alcidion of approximately \$23.3M over six years
- Contract relates to Alcidion's announcement to the market on 15th April 2021

Melbourne, Australia: Alcidion Group Limited (ASX:ALC) today advises that it is a member of a consortium that has been awarded the contract to provide components of an enterprise Health IT Project for the Commonwealth of Australia .

The Consortium is led by Leidos Australia as the prime in a contract. Leidos (NYSE:LDOS) - parent company - is a global IT and engineering consulting firm. The Consortium involves several other digital health partners, many of them leading Australian providers, to deliver the full system requirements. More than 95% of the work will be delivered by Australian companies.

Alcidion will provide the Longitudinal Health Record via its Miya Precision product. The Miya Precision platform will aggregate data from Consortium partner solutions and other systems in the environment to establish a consolidated view of every participant health status and history.

The value of Alcidion's contract is estimated to be \$23.3M over six years. This will cover implementation and a subscription to the Miya Precision platform. Project commencement is planned for December 2021. Further options to take up Miya Observations and Assessments and options to renew up to 15 years creates a possible TCV for the contract with Leidos of around \$50M.

The contract signing follows Alcidion's announcement on 15th April 2021 announcing the company was selected as part of a consortium as the preferred vendor.

Managing Director and CEO Kate Quirke said: "Alcidion looks forward to working with Leidos and our Consortium partners to deliver this significant project. The scale and scope are a validation of Miya Precision's existing capability to provide this critically important longitudinal health record".

This announcement is authorised for release by the Board of Directors of Alcidion Group Limited.

END

For further information, please contact:

Kerstin Wahlqvist
Investor Relations Manager
investor@alcidion.com

About Alcidion Group Limited (ASX:ALC)

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 300 hospitals and 60 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2021. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.